Sachs

More widespread use of powerful weight-loss drugs like Ozempic in the U.S. could boost the economy in the coming years, according to Goldman Sachs strategists.  The bank estimates that weight-loss drugs, called GLP-1 agonists, could increase the nation’s gross domestic product by an extra 1% over the next decade, the equivalent of about $360 billion per year.  … Read more